Drug Type Bispecific antibody |
Synonyms LAVA-039 |
Target |
Mechanism CD1d inhibitors(CD1d antigens inhibitors), TCRDV2 inhibitors(T cell receptor delta variable 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | NL | 07 Mar 2022 |